Drug Search Results
More Filters [+]

Azimilide

Alternative Names: azimilide
Latest Update: 2017-02-01
Latest Update Note: Clinical Trial Update

Product Description

Azimilide is an investigational class III agent with electrophysiological effects on the repolarization phase of the cardiac action potential that are similar to amiodarone.  (Sourced from: https://www.ahajournals.org/doi/10.1161/01.cir.0000151357.36405.72)

Mechanisms of Action: Potassium Channel Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azimilide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Ventricular Fibrillation|Cardiac Arrhythmias|Other|Tachycardia, Ventricular|Atrial Fibrillation

Phase 2: Heart Failure

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-004376-11

P3

Terminated

Unknown

2014-11-15

SHIELD-2

P3

Terminated

Cardiac Arrhythmias

2013-05-01

NCT00752596

P2

Completed

Heart Failure

2006-07-01

NCT00318838

P1

Completed

Healthy Volunteers

2006-05-01

Recent News Events

Date

Type

Title